Abstract 1140P
Background
Patients with advanced melanoma are facing questions regarding their disease, their treatment, or potential signs and symptoms that are common, though predictable. Strategies to control symptoms include targeting patient education and unhealthy behaviors. In the context of an increasingly digital healthcare system, it is worth considering the role of mobile health applications (mHealth) as patient empowerment tools for routine care, patient education and treatment management. To support patients in their daily-life, a digital solution, called TAVIE Skin, was developed; dedicated to all BRAF-mutant unresectable or metastatic melanoma patients who are treated with targeted therapies.
Methods
The intended goal of the TAVIE Skin app is (i) to deliver the necessary information and education support to the patient in regards with their disease and medications, through virtual nurse coaching, (ii) to keep track of medications to improve adherence, (iii) to assist patients in identifying side effects using the virtual nurse coaching and side effects library, and (iv) to engage them towards sustainable healthy behaviors thanks to lifestyle interventions, health trackers and real time coaching. In addition, an optional patient survey is incorporated into the TAVIE Skin app to assess patient reported outcomes, after an e-consent is signed via the app. Ethics approval will be obtained before data collection as per local regulations.
Results
The application will be available in 5 European countries in 2020, and in other countries in 2021. The survey will include 400 patients and will allow for describing the users’ profile of TAVIE Skin app, for assessing HRQoL, including physical, emotional, social, and functional well-being, treatment adherence, as well as work productivity and activity impairment upon targeted therapy. The patients’ satisfaction toward their melanoma treatment, and toward the application will be also assessed.
Conclusions
To the best of our knowledge, TAVIE Skin is the first mHealth application dedicated to patients with BRAF-mutant advanced melanoma. At this year's ESMO Congress, a description of the app, the survey and their objectives will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pierre Fabre.
Funding
Pierre Fabre.
Disclosure
P. Mohr: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: GSK; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pierre Fabre. A. Tadmouri, J. Suissa, M. Alivon: Full/Part-time employment: Pierre Fabre. N. Meyer: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Pierre Fabre; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: AbbVie.